This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wierzbicki, A. S. Articles by Crook, M. A. Search for Related Content PubMed PubMed Citation Articles by Wierzbicki, A. S. Articles by Crook, M. A. Related Collections Lipids ACE/Angiotension receptors Risk Factors Chronic ischemic heart disease Genetics of cardiovascular disease

(Hypertension. 2000;36:808.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Renin-Angiotensin System Polymorphisms and Coronary Events in Familial Hypercholesterolemia

Anthony S. Wierzbicki; Michelle Lambert-Hammill; Peter J. Lumb; Martin A. Crook

From the Lipid Unit, Department of Chemical Pathology, King’s College, London (Guy’s, King’s, and St Thomas’ Medical School), St Thomas’ Hospital Campus, London, UK.

Correspondence to Dr A.S. Wierzbicki, Department of Chemical Pathology, St Thomas’ Hospital, Lambeth Palace Rd, London SE1 7EH, UK.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—The role of renin-angiotensin system polymorphisms as risk factors for coronary heart disease (CHD) is controversial. This study investigated their role in patients with heterozygous familial hypercholesterolemia (FH). Polymorphism frequencies for angiotensin-I–converting enzyme insertion/deletion (ACE I/D), angiotensinogen M235T, and angiotensin-II type I receptor (AG2R) A1166C were determined in 112 patients with FH and 72 patients with polygenic hypercholesterolemia, of whom 26.7% and 41.6%, respectively, had established CHD. None of the polymorphisms were associated with risk of CHD in patients with polygenic hypercholesterolemia in this study. Logistic regression analysis of risk factors for CHD in patients with FH identified male sex (odds ratio [OR]=3.03; 95% CI, 3.07 to 3.72; P=0.05), smoking (OR=2.91; 95% CI, 2.16 to 4.24; P=0.05), diastolic blood pressure (OR=3.70; 95% CI, 3.43 to 3.97; P=0.02), plasma glucose (OR=3.31; 95% CI, 3.10 to 3.52; P=0.04), and the AG2R A1166C polymorphism as risk factors. The OR for the AG2R A1166C polymorphism was 2.26 (95% CI, 1.26 to 3.72; P=0.06) and increased to 3.10 (95% CI, 1.20 to 7.52; P=0.04) after adjustment for other risk factors. The AG2R A1166C polymorphism may interact with severe hypercholesterolemia and other risk factors to increase risk of CHD in FH patients.

Key Words: familial hypercholesterolemia • coronary artery disease • renin-angiotensin system • genetics

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Familial hypercholesterolemia (FH) is an autosomal dominant disorder of clearance of LDL cholesterol and is associated with premature coronary artery disease. It clinical features include hypercholesterolemia, tendon xanthomata, arcus, and premature atherosclerosis.¹ Patients with heterozygous hypercholesterolemia have significant excess risk at younger ages, although this tends to fall with age to levels 3- to 8-fold greater than those in age- and sex-matched controls.^{1 2} The age of onset of coronary heart disease (CHD) in individual families is similar but only moderately correlated with LDL cholesterol concentration and type of mutation.³ Hence, it is likely that genetic factors beyond the LDL receptor play a role in determining the incidence of CHD in heterozygous FH.

The renin-angiotensin system plays a critical role in the control of blood pressure, which is a significant risk factor for atherosclerosis and cardiovascular disease. Recently, polymorphisms in the 3 genes in the renin-angiotensin system—angiotensin-I–converting enzyme deletion/insertion (ACE I/D), the angiotensinogen gene methionine-235 threonine (AGT M235T), and the angiotensin II type I receptor (AG2R) A1166C—have been postulated as risk factors for CHD in patients with polygenic hyperlipidemia.^{4 5 6} However, the role of these polymorphisms in cardiovascular disease in FH has never been explored. This study examined the role of renin-angiotensin polymorphisms in determining the risk of CHD in patients with FH or polygenic hyperlipidemia.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
One hundred twelve patients with clinical heterozygous FH aged >40 years and 72 patients with polygenic hyperlipidemia were recruited from the lipid clinics of Guy’s and St Thomas’ hospitals with local hospital ethical committee permission and after individual informed medical consent had been obtained. The diagnosis of FH was made by Simon Broome Register criteria^{1 2} : the presence of an autosomal dominant family history of CHD before age 60 years in first-degree or age 50 years in second-degree relatives, LDL >5.7 mmol/L (220 mg/dL), and the presence of tendon xanthomata for a definite, as opposed to a probable, diagnosis. The diagnostic criteria for polygenic hyperlipidemia were absence of history of CHD in a first- or second-degree relative before age 70 years. Patients with hypercholesterolemia and triglycerides >5 mmol/L (442 mg/dL) with positive family histories for CHD were excluded on grounds of possible familial combined hyperlipidemia.

All patients had been reviewed in the clinic for at least 6 years and had undergone exercise testing a minimum of 5 times per year; those with suboptimal exercise tolerance underwent thallium cardiac scintigraphy or stress echocardiography. Coronary artery disease was diagnosed on the basis of confirmed cardiac event, angioplasty, coronary bypass surgery, or angina with significant lesions visible on angiography.

Clinical Risk Factors
Cigarette smoking was certified by self-assessment at the time of the study, and subjects were classified as nonsmoker, ex-smoker, or current smoker. Body mass index was calculated as weight/height². Hypertension was diagnosed by either treatment or blood pressure >140 mm Hg systolic and >90 mm Hg diastolic. Tendon xanthomata and arcus were assessed clinically.

Biochemical Analyses
A full biochemical profile, including urea and electrolytes, liver function tests, thyroid function test, creatine kinase, fasting lipids (total, LDL, and HDL cholesterol and triglycerides), and lipoprotein(a) [Lp(a)], was performed after a 16-hour fast. Baseline lipids were assessed after subjects had discontinued drug therapy for 4 weeks. Lipids were measured by automated techniques on a Vitros 950 analyzer and apolipoproteins on a Behring BN2 analyzer. Fasting plasma homocysteine was measured by high-performance liquid chromatography.

Determination of Genotypes
DNA was extracted from fresh lymphocytes by a standard method (Puregene, [Gentra] Flowgen). Polymorphisms in genes including the ACE I/D, AGT M235T, and AG2R A1166C were assessed by amplification with the use of standard cited primers followed by restriction digestion.^{7 8 9} The presence of I alleles was confirmed by amplification of the ACE gene in 5% dimethyl sulfoxide and by independent confirmation with the use of an I allele–specific primer pair.^{10 11} Restriction fragments were separated by electrophoresis on 2% to 4% agarose gels and typed by 2 independent observers blinded to the clinical data. Genotype frequencies were compared with 100 randomly selected healthy control samples to assess significant sampling errors in genotypes from the local population. The presence of familial defective apolipoprotein B₃₅₀₀ was excluded by polymerase chain reaction amplification and a standard restriction digestion method.¹²

Statistical Analysis
Data were analyzed with the use of GBStat version 6.5 software (Dynamic Microsystems Inc). Differences in normally distributed variables were analyzed by Student’s t test and in nonnormally distributed variables by Wilcoxon signed rank test. The allele frequencies of cases and controls and deviation from Hardy-Weinberg equilibrium were analyzed by ² test (with Yates correction). A 2-tailed P value <0.05 was considered significant.

We employed a logistic regression model using all clinically measured variables to assess the effects of genotypes and risk factors separately and combined. Risk factors included in the model compared presence of CHD with age, sex, smoking status, presence of diabetes mellitus, systolic and diastolic blood pressure, plasma glucose, LDL, HDL, log triglycerides, and log Lp(a). After selection of significant environmental risk factors from the original model, modeling was repeated with addition of genetic variables. Models applying recessive inheritance, dominant inheritance, or codominant gene effects were tested for assessment of genetic effects on coronary artery disease risk.

Power calculations showed that for n=30 in the CHD(+) group and n=60 in the CHD(-) group, the study had a power of 80% to detect a difference of 5% in AG2R, 10% in angiotensinogen, and 15% in ACE genotypes. Odds ratios (OR) were recalculated after adjustment for other risk factors by ANCOVA. Population attributable risk (PAR%) was calculated as a percentage according to the formula PAR%=100 [(Prev_E)(OR-1)/1+(Prev_E)(OR-1)], where prevalence of exposure (Prev_E) was assumed to be the AG2R 1166C allele frequency and OR was the odds ratio for association of CHD with the AG2R 1166C allele.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Characterization of Subjects
A total of 184 subjects were included in the study. Patient characteristics are shown in Table 1. The median follow-up for patients with FH was 7.5 years (range, 6 to 25 years). FH patients were 9.2 years younger and had established CHD 11 years earlier than patients with polygenic hyperlipidemia. They had higher total and LDL cholesterol concentrations than polygenic patients and had higher rates of smoking in men with CHD (P<0.001). The incidence of CHD was slightly lower in the FH population than in patients with polygenic hyperlipidemia, although this was not significant. All other differences between the 2 groups were not significant.

View this table: [in this window] [in a new window]   Table 1. Characteristics of Patients With FH or Polygenic Hyperlipidemia With and Without CHD

Risk Modeling
Logistic regression modeling identified male sex (OR=3.03; 95% CI, 3.07 to 3.72; P=0.05;), smoking (OR=2.91; 95% CI, 2.16 to 4.24; P=0.05), diastolic blood pressure (OR=3.70; 95% CI, 3.43 to 3.97; P=0.02), plasma glucose (OR=3.31; 95% CI, 3.10 to 3.52; P=0.04), and the AG2R1166C allele (OR=3.11; 95% CI, 1.20 to 7.52; P=0.04) as significant risk factors for CHD in patients with FH. Other risk factors including total (or LDL) cholesterol (OR=2.29; 95% CI, 0.89 to 3.20; P=0.09) and Lp(a) (OR=1.99; 95% CI, 0.70 to 3.26; P=0.12) showed a slight association in the environmental risk factor model but did not reach statistical significance and therefore were omitted in combined environmental-genetic interaction modeling.

Genotype Analyses
The results of genotype analysis are shown by genotype and allele group in Tables 2 and 3. Allele frequencies in the groups without CHD did not differ significantly from those in the healthy control group. All allele frequencies were in Hardy-Weinberg equilibrium. Initial uncorrected analysis (Table 3) showed no associations of any polymorphisms with CHD except for ACE-D (P=0.03). The second strongest relationship was for AG2R A1166C, with an OR of 2.26 (95% CI, 1.26 to 3.72; P=0.06). After adjustment for other risk factors, as detailed above, no association was found with CHD risk and ACE-D, but the OR for association of risk of CHD with the AG2R polymorphism was increased to 3.10 (95% CI, 1.20 to 7.52; P=0.04).

View this table: [in this window] [in a new window]   Table 2. Unadjusted Risks for the Incidence of CHD Between Different Genotype Groups

View this table: [in this window] [in a new window]   Table 3. Allele Frequencies in Patients With and Without CHD and FH or Polygenic Hyperlipidemia and Control Subjects

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
A number of factors, including age, sex, smoking, and HDL concentrations, have previously been identified as risk factors for CHD in FH in cross-sectional studies.^{1 2 3 13 14 15 16 17 18} Logistic regression modeling of this admittedly small population identified risk factors similar to those in these large studies, indicating that the population studied was likely to be representative.¹³ In this study, as in the large cohort study of 526 patients in the United Kingdom with heterozygous FH, LDL was a poor predictor of the risk for CHD,¹ in contrast to epidemiological studies of patients with polygenic hyperlipidemia. In addition, data from a cohort of 263 patients with identical LDL receptor mutations have shown that LDL was only a risk factor for CHD in women, and this study included relatively few women.¹⁶ Patients included in this study were identified by clinical diagnosis with the use of the Simon Broome Registry criteria. Previous studies in a similar population in North London had indicated that the prevalence of LDL receptor mutations in this heterogeneous population was likely to be 20% in tendon xanthoma–negative patients and 50% in tendon xanthoma–positive patients, with an overall average of 33%.¹⁷ Data on the study population are unavailable at this time. Although this population is heterogeneous, clinically it has the phenotype of familial hypercholesterolemia. Such populations have been used as the basis of epidemiological studies to identify additional risk factors for early CHD in FH, eg, the Simon Broome Register Project,^{1 2} and in other studies of genetic risk factors for CHD in FH.¹⁸ The study was small but similar in size to other studies of this disorder^{16 18} and derived its power from sampling the extremes of the distribution curve due to the 5- to 9-fold excess risk of CHD in patients with FH, particularly men, before age 50 years (even on treatment) compared with unaffected patients with FH.^{1 2 19}

This study investigated the role of renin-angiotensin polymorphisms, which have been posited as risk factors in polygenic hyperlipidemia in a heterogeneous white population with FH. Allele frequencies in this study were representative of white populations and did not show significant sampling errors when compared with data from other similar populations.^{13 18}

The role of renin-angiotensin system polymorphisms in CHD in patients with polygenic hyperlipidemia is controversial, with conflicting results from different studies. The ACE-D allele is associated with higher ACE levels,²⁰ and meta-analyses tend to support a weak role for these polymorphisms in CHD, with a relative risk of 1.1 to 1.3.^{21 22 23} In this study no association was found between any renin-angiotensin system polymorphism and risk of CHD in the patients with polygenic hyperlipidemia.

Few studies have explored the role of the renin-angiotensin system as genetic risk factor in FH. One previous study in a heterogeneous US cohort that included patients with both FH and familial defective apolipoprotein B₃₅₀₀ identified male sex (OR=3.38), smoking (OR=3.71), and ACE DD genotype (OR=2.21) as risk factors for CHD.¹⁸ That study had an ACE-D allele frequency of 0.55, similar to this study, but the significant association with CHD was only found in men, in whom the D allele frequency was increased to 0.70. The study had a power of 80% to detect a difference of 15% in allele frequencies. In contrast, this study, of similar power, while confirming the relative strength of male sex (OR=3.03) and smoking (OR= 2.91) as risk factors, also identified diastolic blood pressure (OR=3.70) and glucose (OR= 3.31) as significant risk factors. However, it was unable to demonstrate an association of ACE genotype with risk of CHD overall or in men or women after correction for other risk factors. When the results of both studies on ACE genotypes in FH are combined, no association of CHD with ACE genotype is seen (²=1.18; P=0.27; OR=1.35; 95% CI, 0.83 to 2.19 for ACE-D). This suggests that larger studies may be needed to clarify the role of ACE genotypes as risk factors for CHD in patients with FH.

The interaction of renin-angiotensin system polymorphisms may be complex since the ACE-D allele may interact with the AG2R 1166C allele to increase risks of CHD.⁶ AG2R polymorphisms were not assessed in the previous study of CHD in FH patients, yet this study did find an association of CHD with the AG2R genotype, with a relative risk of 2.26 (95% CI, 1.26 to 3.72) increased to 3.10 (95% CI, 1.20 to 7.52) after adjustment for other environmental risk factors, including age, sex, blood pressure, and smoking. Analysis by sex, although limited by small numbers, particularly in women, showed that the principal effect of the AG2R polymorphism was seen in men (OR=3.56; 95% CI, 1.95 to 14.04; P=0.005) compared with women (OR=1.20; 95% CI, 0.20 to 7.19; P=0.64). This suggests that the effects of the polymorphism are greater in higher-risk individuals. The study was too small for formal genetic tests of interaction, but the use of a multiplicative model for ACE and AG2R polymorphisms, with double homozygotes being assigned a score of 1 and 4, respectively, showed no association with CHD above that for the AG2R polymorphism alone, although it was limited by the small number of AG2R C₁₁₆₆ homozygotes.

Hypercholesterolemia has been associated with endothelial dysfunction,²⁴ increased oxidative stress,²⁴ increased expression of AG2R,²⁵ and a left shift in the angiotensin II dose-response curve,²⁶ some of which can be corrected by AG2R antagonists in animal models.²⁷ The functional consequence of severe hypercholesterolemia with increased angiotensin II production (via ACE) and increased receptor expression or sensitivity could be increased rates of CHD. The AG2R A1166C polymorphism, which was a significant risk factor for CHD in this study, has been associated with increased coronary arterial vasoconstriction,²⁸ aortic stiffness,²⁹ and arterial angiotensin II responsiveness,³⁰ all of which could predispose to increased risk of CHD. Calculation of population attributable risk using an assumption of a 3.1-fold excess risk for the 1166C allele would suggest that the AG2R genotype may account for up to 16% of attributable risk for CHD in patients with FH. However, this should be treated with caution because the ACE-D polymorphism in the study by O’Malley et al¹⁸ would be expected to account for 41%. Reports of the association of AG2R polymorphisms with CHD are conflicting,²¹ but if the full AG2R phenotype predisposing to CHD is dependent on LDL concentration for expression, then effects might be less in normolipidemic as opposed to severely hypercholesterolemic populations. Similarly, lesser effects would be expected in nonsmokers and women. The contrasting findings of this study in polygenic hypercholesterolemia as opposed to FH would support such a hypothesis. None of the meta-analyses of AG2R polymorphisms to date have investigated the association of the CHD phenotype with LDL concentration as a covariable.^{21 22} However, the possibility of type I error due to sampling differences, as may have occurred with ACE-I, cannot be completely excluded in studies of this size, especially with polymorphisms with highly asymmetric allele distributions. Given the conflicting results with respect to ACE genotype and risk of CHD in FH to date, larger studies will be required in the FH population to confirm whether the C1166 allele is a risk factor for CHD in this group.

In summary, this study showed no association of ACE-D or AGT M235T with CHD in patients with FH or in patients with polygenic hyperlipidemia. However, an association was demonstrated for the AG2R A1166C polymorphism in FH patients. Thus, AG2R polymorphisms may interact with hypercholesterolemia and other cardiovascular risk factors to increase the risk of CHD in FH.

Received February 11, 2000; first decision March 8, 2000; accepted May 22, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J. 1991;303:893–896.

2. Simon Broome Register Group. Mortality in treated heterozygous familial hyper-cholesterolaemia: implications for clinical management. Atherosclerosis. 1999;142:105–112.[Medline] [Order article via Infotrieve]

3. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 1995;92:290–295.[Abstract/Free Full Text]

4. Cambien F, Poirier O, Lecerf O, Evans AE, Cambou JP, Arveiler D, Luc G, Bard J-M., Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644.[Medline] [Order article via Infotrieve]

5. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S, Nyuui N, Kimura K, Miyazaki N, Ishii M. Molecular variant of angiotensinogen is associated with coronary artery disease. Circulation. 1995;91:951–954.[Abstract/Free Full Text]

6. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P, Soubrier F, Cambien F. Synergistic effects of angiotensin-I converting enzyme and angiotensin II type I receptor polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910–913.[Medline] [Order article via Infotrieve]

7. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucl Acid Res. 1992;20:1433.[Free Full Text]

8. Russ AP, Maertz W, Ruzicka V, Stein U Gross W. Rapid detection of the hypertension-associated Met235174 12Thr allele of the human angiotensinogen gene. Hum Mol Genet. 1993;2:609–610.[Free Full Text]

9. Hingorani AD, Brown MJ. A simple molecular assay for the C¹¹⁶⁶ variant of the angiotensin II type I receptor. Biochem Biophys Res Commun. 1995;213:725–729.[Medline] [Order article via Infotrieve]

10. Lindpainter K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, la Motte F, Buring J, Hennekens CH. A prospective evaluation of the angiotensin-converting enzyme gene polymorphism in the risk of ischemic heart disease. N Engl J Med. 1995;332:706–711.[Abstract/Free Full Text]

11. Wierzbicki AS, Nimmo L, Feher MD, Cox A, Foxton J, Lant AF. Association of the angiotensin converting enzyme DD genotype with hypertension in diabetes. J Hum Hypertens. 1995;9:671–673.[Medline] [Order article via Infotrieve]

12. Hansen PS, Rudiger N, Tybaerg-Hansen A, Faergeman O, Gregersen N. Detection of the apoB₃₅₀₀ (glutamine for arginine) by gene amplification and cleavage with Msp I. J Lipid Res. 1991;32:1229–1233.

13. Mabuchi H, Koizumi J, Shimuzu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 1989;79:225–232.[Abstract/Free Full Text]

14. Schuster H, Humphries SE. European Workshop on LDL receptor defects: European Working Group on Familial Hypercholesterolaemia. Clin Invest. 1994;72:898–907.[Medline] [Order article via Infotrieve]

15. Moorjani S, Roy M, Torres A, Betard C, Gagne C, Lambert M, Brun D, Davignon J, Lupien P. Mutations of low density lipoprotein receptor, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341:1303–1306.[Medline] [Order article via Infotrieve]

16. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor mutation. Circulation. 1995;92:290–295.

17. Day IN, Whittall RA, O’Dell SD, Haddad L, Bolla MK, Gudnason V, Humphries SE. Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolaemia. Hum Mutat. 1997;10:116–127.[Medline] [Order article via Infotrieve]

18. O’Malley JP, Maslen CL, Illingworth R. Angiotensin-converting enzyme DD genotype and cardiovascular risk in heterozygous familial hypercholesterolemia. Circulation. 1998;97:1780–1783.[Abstract/Free Full Text]

19. Sijbarnds EJG, Westendorp RGJ, Lombardi MP, Havelkes LM, Frants RR, Kastelein JJP, Smelt AHM. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis.. 2000;149:421–425.[Medline] [Order article via Infotrieve]

20. Rigat B, Hubert C, Alhene-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in angiotensin I-converting enzyme accounting for one half the variance in serum enzyme levels. J Clin Invest. 1990;86:1343–1346.

21. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R, Fagard R. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1997;4:401–422.[Medline] [Order article via Infotrieve]

22. Samani N, Thompson JR, O’Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation. 1996;94:708–712.[Abstract/Free Full Text]

23. Singer DRJ, Missouris CG, Jeffrey S. Angiotensin-converting enzyme gene polymorphisms: what to do about all the confusion? Circulation. 1996;94:236–239.[Free Full Text]

24. Anderson TJ. Assessment and treatment of endothelial dysfunction. J Am Coll Cardiol. 1999;34:631–638.[Free Full Text]

25. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473–478.[Abstract/Free Full Text]

26. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131–2134.[Abstract/Free Full Text]

27. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin II receptor antagonist losartan inhibits LDL peroxidation and atherosclerosis in apolipoprotein E deficient mice. Biochem Biophys Res Commun. 1997;236:622–625.[Medline] [Order article via Infotrieve]

28. Amant C, Hamon M, Bauters C, Richard F, Helbecque RF, McFadden EP, Escudero X, Lablanche JM, Amouyel P, Bertrand ME. The angiotensin II type I receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol. 1997;29:486–490.[Abstract]

29. Benetos A, Topouchian J, Ricard S, Gautier RS, Bonnardeaux A, Asmar R, Poirier O, Soubrier F, Safar M, Cambeien F. Influence of the angiotensin II type I receptor polymorphism on aortic stiffness in never-treated hypertensive patients. Hypertension. 1995;26:44–47.[Abstract/Free Full Text]

30. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJGM, van Gilst WK. Angiotensin II type I receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension.. 2000;35:717–721.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. B. van der Net, J. van Etten, M. Yazdanpanah, G. M. Dallinga-Thie, J. J.P. Kastelein, J. C. Defesche, R. P. Koopmans, E. W. Steyerberg, and E. J.G. Sijbrands Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia Eur. Heart J., June 1, 2008; 29(11): 1370 - 1376. [Abstract] [Full Text] [PDF]

				E. Zintzaras, G. Raman, G. Kitsios, and J. Lau Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphic Variant as a Marker of Coronary Artery Disease: A Meta-analysis Arch Intern Med, May 26, 2008; 168(10): 1077 - 1089. [Abstract] [Full Text] [PDF]

				M.-Q. Xu, Z. Ye, F. B. Hu, and L. He Quantitative Assessment of the Effect of Angiotensinogen Gene Polymorphisms on the Risk of Coronary Heart Disease Circulation, September 18, 2007; 116(12): 1356 - 1366. [Abstract] [Full Text] [PDF]

				P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]

				M R Abdollahi, T R Gaunt, H E Syddall, C Cooper, D I W Phillips, S Ye, and I N M Day Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits J. Med. Genet., May 1, 2005; 42(5): 396 - 401. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wierzbicki, A. S. Articles by Crook, M. A. Search for Related Content PubMed PubMed Citation Articles by Wierzbicki, A. S. Articles by Crook, M. A. Related Collections Lipids ACE/Angiotension receptors Risk Factors Chronic ischemic heart disease Genetics of cardiovascular disease